Patients with advanced-stage neuroendocrine tumours (NETs) have limited treatment options following disease progression after 1–2 lines of systemic therapy. Now, newly published data from the phase III CABINET trial, simultaneously presented at the ESMO Congress 2024, demonstrate the efficacy of cabozantinib in this setting.

In CABINET, patients with locally advanced or metastatic well or moderately differentiated extrapancreatic (n = 203) or pancreatic (n = 95) NETs previously treated with at least one FDA-approved systemic therapy were randomly assigned, 2:1, to either cabozantinib or placebo. Most patients had received 177Lu-dotatate (~59%) and/or everolimus (~72%), and ~26% of those with pancreatic NETs had received sunitinib. Progression-free survival (PFS) was the primary end point.